{"nctId":"NCT02042014","briefTitle":"Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan","startDateStruct":{"date":"2014-01-22","type":"ACTUAL"},"conditions":["Severe Pulmonary Arterial Hypertension"],"count":8,"armGroups":[{"label":"QTI571","type":"EXPERIMENTAL","interventionNames":["Drug: QTI571"]}],"interventions":[{"name":"QTI571","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan.\n* Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator.\n\nExclusion Criteria:\n\n* Patient has been permanently discontinued from QTI571 study treatment in the parent study.\n* Concomitant use of oral vitamin K antagonist medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serious Adverse Events","description":"All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":8},"commonTop":[]}}}